| Application no. and date | 13751007.9 (espacenet) (Federated) (European Patent Register), 20130808 | | Patent/reg. no. and date | DK/EP 2882442, 20210609 | | Publication date | 20150617 | | Priority no. and date | US 201261681447 P, 20120809, US 201261722727 P, 20121105 | | EP pub. no. and date |
EP 2882442 20150617 | | Effective date | | | Applicant/owner | Celgene Corporation, 86 Morris Avenue
Summit, NJ 07901, US | | Applicant ref. no. | P77262DK01 | | Inventor | SCHAFER, Peter, H., 237 Monroe Avenue
Belle Mead, NJ 08502, US,
GANDHI, Anita, 37 Stirling Road
Bernardsville, NJ 07924, US | | Representative | Plougmann Vingtoft A/S, Strandvejen 70, 2900 Hellerup, DK | | Opponent | | | IPC Class | A61K 31/5377 (2006.01) , A61K 45/06 (2006.01) , A61P 35/00 (2006.01) , A61P 35/02 (2006.01) , A61P 43/00 (2006.01) , G01N 33/50 (2006.01) | | Title | FREMGANGSMÅDER TIL BEHANDLING AF CANCER UNDER ANVENDELSE AF 3-(4-((4-(MORPHOLINOMETHYL)BENZYL)OXY)-1-OXOISOINDOLIN-2-YL)PIPERIDIN-2,6-DION | | Int. application no. | US2013054055 | | Int. publication no. | WO2014025960 | | Related patent (certificate) | | | Status | DK/EP patent | | Pædiatrisk forlængelse | - | | Udløbsdato for pædiatrisk forlængelse | - |
|
